Relationship between Dose Discontinuation or Dose Reduction for Safety Reasons in Clinical Trials and Lower-dose Prescriptions in the Post-marketing Setting
Dosage of pharmaceuticals is determined and approved based on pivotal clinical trial results in Phase 3. However, in the post-marketing setting, it is often adjusted according to conditions of individual patients. Some pharmaceuticals are used at a lower dose than the approved dose for safety reasons or in elderly patients. In this study, we examined the relationships between dose discontinuation or dose reduction, for safety reasons as well as participation of elderly patients in clinical trials, and lower-dose prescriptions in the post-marketing setting. We collated the dataset of 113 eligible pharmaceuticals from those that were approved in Japan between 2005 and 2014. Subsequently, we calculated the proportions of patients who withdrew from the study, whose medication was discontinued, or dose reduced due to adverse events, and of elderly patients (over sixty-five years old) to those who were exposed to the approved dose range in the pivotal clinical trials. Then their relationships with lower-dose prescription in the post-marketing setting were examined using Mann-Whitney U test. The proportions of patients who withdrew from the study (p=0.0019), whose medication was discontinued owing to adverse events (p=0.0007), or whose dose was reduced owing to adverse events (p<0.0001) were significantly higher for "lower-dose prescription drugs" than those for other drugs; however, the proportion of elderly patients did not show this significant increase in the "lower-dose prescription drugs" group.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:141 |
|---|---|
| Enthalten in: |
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan - 141(2021), 5 vom: 25., Seite 743-749 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Ogata, Akiko [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse event |
|---|
| Anmerkungen: |
Date Completed 29.10.2021 Date Revised 29.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1248/yakushi.20-00234 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325055319 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325055319 | ||
| 003 | DE-627 | ||
| 005 | 20231225191626.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.1248/yakushi.20-00234 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM325055319 | ||
| 035 | |a (NLM)33952758 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Ogata, Akiko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Relationship between Dose Discontinuation or Dose Reduction for Safety Reasons in Clinical Trials and Lower-dose Prescriptions in the Post-marketing Setting |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.10.2021 | ||
| 500 | |a Date Revised 29.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Dosage of pharmaceuticals is determined and approved based on pivotal clinical trial results in Phase 3. However, in the post-marketing setting, it is often adjusted according to conditions of individual patients. Some pharmaceuticals are used at a lower dose than the approved dose for safety reasons or in elderly patients. In this study, we examined the relationships between dose discontinuation or dose reduction, for safety reasons as well as participation of elderly patients in clinical trials, and lower-dose prescriptions in the post-marketing setting. We collated the dataset of 113 eligible pharmaceuticals from those that were approved in Japan between 2005 and 2014. Subsequently, we calculated the proportions of patients who withdrew from the study, whose medication was discontinued, or dose reduced due to adverse events, and of elderly patients (over sixty-five years old) to those who were exposed to the approved dose range in the pivotal clinical trials. Then their relationships with lower-dose prescription in the post-marketing setting were examined using Mann-Whitney U test. The proportions of patients who withdrew from the study (p=0.0019), whose medication was discontinued owing to adverse events (p=0.0007), or whose dose was reduced owing to adverse events (p<0.0001) were significantly higher for "lower-dose prescription drugs" than those for other drugs; however, the proportion of elderly patients did not show this significant increase in the "lower-dose prescription drugs" group | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adverse event | |
| 650 | 4 | |a dose reduction | |
| 650 | 4 | |a elderly patient | |
| 650 | 4 | |a lower dose | |
| 650 | 4 | |a post-marketing | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Narukawa, Mamoru |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan |d 1961 |g 141(2021), 5 vom: 25., Seite 743-749 |w (DE-627)NLM000042153 |x 1347-5231 |7 nnns |
| 773 | 1 | 8 | |g volume:141 |g year:2021 |g number:5 |g day:25 |g pages:743-749 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1248/yakushi.20-00234 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 141 |j 2021 |e 5 |b 25 |h 743-749 | ||